Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

323,078 803,754 923,172 2,489,996

Purchased research

and development 6,556,048 - 6,556,048 -

Selling, general

and administrative 1,767,587 622,518 2,812,002 1,843,534

Total operating

expenses 8,646,713 1,435,717 10,292,778 4,395,264

Loss from operations (8,634,213) (1,412,538) (10,243,158) (4,320,144)

Other income (Expense):

Interest income 21,657 28,604 35,563 109,687

Interest expense (64,131) (4,469) (70,289) (14,439)

Other income, net (42,474) 24,135 (34,726) 95,248

Net loss (8,676,687) (1,388,403) (10,277,884) (4,224,896)

Accretion of dividend on

Series A Convertible

Preferred Stock - (1,479) (483) (4,389)

Net loss applicable

to common

shareholders $(8,676,687) $(1,389,882) $(10,278,367) $(4,229,285)

Net loss per common share,

basic and diluted $(0.70) $(0.49) $(1.05) $(1.60)

Basic and diluted weighted

average common shares

outstanding 12,438,201 2,839,201 9,771,183 2,640,691


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... 2010 AVANIR Pharmaceuticals, Inc. (Nasdaq: ... offer and sell shares of its common stock in an ... sole book-running manager in the offering and Canaccord Genuity Inc., ... Capital are acting as co-managers for the offering.  In addition ...
... a leading Clinical Research Organization, announces that the head ... speak at the 3rd annual China Drug Safety and ... 2010. Dr. Sabine Richter, PRA,s Vice President ... "Challenges of Drug Safety in Global Clinical Trials." Her ...
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
Cached Biology Technology:AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock 2PRA International Expert to Speak at China Drug Safety Summit 2Enerkem adds two new executive roles to growing North American presence 2Enerkem adds two new executive roles to growing North American presence 3Enerkem adds two new executive roles to growing North American presence 4Enerkem adds two new executive roles to growing North American presence 5Enerkem adds two new executive roles to growing North American presence 6Enerkem adds two new executive roles to growing North American presence 7
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... understanding the basis of coral reef recovery, researchers have ... pinnatus, in promoting the return to health of a ... to light a previously unrecognized role for the batfish ... in reef recovery after overfishing. In doing so, the ...
... developed a new method to identify the "DNA-binding transcription factors" ... of cells that ultimately make up all the organs and ... were made using mouse embryonic spinal cord as a model, ... National Academy of Sciences, a professional journal. , The ...
... have discovered why the aging brain produces progressively ... memory center. The scientists said the finding, made ... crucial "progenitor" stem cells persist in the aging ... of treating various neurodegenerative disorders, including Alzheimer's disease, ...
Cached Biology News:Fish species plays surprise role in aiding coral reef recovery 2Advance helps explain stem cell behavior 2Advance helps explain stem cell behavior 3Stem cell activity deciphered in the aging brain 2
mCD-1 10 transcription reactions...
... x 2 , Maintenance 112 ... , Immunizations/Boost injections x5 /each ... x1 /each , Production bleed (25 ... Final Bleed ~ 100 ml blood (~50 ml serum) ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
Biology Products: